Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
Brain Hemorrhages
; 2022.
Article
in English
| ScienceDirect | ID: covidwho-1796769
ABSTRACT
Pituitary apoplexy (PA) may complicate the course of coronavirus disease 2019 (COVID-19), posing a potential threat to life. Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states that it can cause very rare coagulation disorders, in particular thrombosis with thrombocytopenia syndrome in some cases accompanied by bleeding, cerebrovascular venous or sinus thrombosis, and thrombocytopenia, including immune thrombocytopenia, also associated with bleeding. Here, we report the onset of PA after Vaxzevria® in a 28-year-old healthy Caucasian female, who experienced long-lasting tension-type headache, hyperprolactinemia and menstrual changes, without thrombocytopenia or thrombosis.
Full text:
Available
Collection:
Databases of international organizations
Database:
ScienceDirect
Topics:
Vaccines
Language:
English
Journal:
Brain Hemorrhages
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS